Shots:
- AstraZeneca & CSPC have partnered to discover & develop pre-clinical candidates for multiple targets across chronic diseases, incl. a pre-clinical oral small molecule for immunological diseases
- As per the deal, CSPC will receive $110M upfront as well as ~$1.62B in development & ~$3.6B in sales milestones with net sales-based single digit royalties, while AstraZeneca will obtain rights to exercise options for exclusive global licenses to develop & commercialize these candidates
- CSPC will lead research in Shijiazhuang City using its AI-driven dual-engine drug discovery platform to analyze target protein–molecule interactions & conduct targeted optimization to identify effective small molecules
Ref: Astrazeneca | Image: Astrazeneca & CSPC Pharmaceuticals| Press Release
Related News: AstraZeneca’s Calquence Regimen Receives the EC’s Approval for 1L Chronic Lymphocytic Leukaemia (CLL)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
